LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals Inc. announced that it has received US Food and Drug Administration (FDA) approval for Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN.
Nexus Pharms' Generic Erythromycin Lactobionate Receives Approval in the U.S.
Exela Pharma's Generic Erythromycin Lactobionate Receives Approval In US
Throughout the year, we will be publishing information on new generic and biosimilar prescription medicines as they are approved. Please note that the sponsor name reflects the information in the Australian Register of Therapeutic Goods (ARTG) at the time of registration. As sponsors may change over time, consult the ARTG for full information in relation to these products, including full indications.